Capravirine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Capravirine
Capravirine.png
Names
IUPAC name
[5-(3,5-Dichlorophenyl)sulfanyl-4-propan-2-yl-1-(pyridin-4-ylmethyl)imidazol-2-yl]methyl carbamate
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
Properties
C20H20Cl2N4O2S
Molar mass 451.37 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

Capravirine was a non-nucleoside reverse transcriptase inhibitor which reached phase II trials before development was discontinued by Pfizer.[1][2] Both phase IIb trials which were conducted failed to demonstrate that therapy with capravirine provided any significant advantage over existing triple-drug HIV therapies, and pharmacology studies showed that capravirine may interact with other HIV drugs.[3][4]

References[edit]

  1. ^ PubChem. "Capravirine". pubchem.ncbi.nlm.nih.gov. Retrieved 2019-06-02.
  2. ^ "Capravirine - Anti-Retroviral Drug". Drug Development Technology. Retrieved 2019-06-02.
  3. ^ "Capravirine - Anti-Retroviral Drug". Drug Development Technology. Retrieved 2019-06-02.
  4. ^ "A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-06-02.